EMEA Reverses Negative Decision On GTC’s Transgenic Antithrombin ATryn
This article was originally published in The Pink Sheet Daily
Executive Summary
GTC Biotherapeutics expects to file a BLA in the U.S. for recombinant human antithrombin in the first half of 2007.
You may also be interested in...
GTC Anticipates Reaching U.S. Market In 2009 With Human Antithrombin ATryn
Company tells “The Pink Sheet” DAILY it will seek indications for larger patient populations than initial target of hereditary antithrombin deficiency.
GTC Anticipates Reaching U.S. Market In 2009 With Human Antithrombin ATryn
Company tells “The Pink Sheet” DAILY it will seek indications for larger patient populations than initial target of hereditary antithrombin deficiency.
Transgenic Goat Antithrombin Gains EU Nod
GTC Biotherapeutics' recombinant human antithrombin ATryn was granted European Union marketing authorization roughly six months after receiving an initial negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use